Patents Assigned to JIANGSU CAPTAIN BIOTECHNOLOGY CO., LTD.
  • Patent number: 11530390
    Abstract: A method for promoting replication of infectious bovine rhinotracheitis viruses using cold atmospheric plasma, including: irradiating a medium for Madin-Darby bovine kidney cells with a cold atmospheric plasma generator; adding the irradiated medium to the Madin-Darby bovine kidney cells; and adding infectious bovine rhinotracheitis viruses for incubation. The time required for treatment is 2 min allowing for a simple and rapid operation. The plasma is used for the indirect treatment of cells with a uniform process and a controllable intensity. The replication of the infectious bovine rhinotracheitis viruses in the Madin-Darby bovine kidney cells is significantly promoted by co-incubation in the treated DMEM for 1 hour, so that the high levels of infectious bovine rhinotracheitis viruses obtained can be used for vaccine production after inactivation, improving the vaccine production efficiency.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 20, 2022
    Assignee: JIANGSU CAPTAIN BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaofeng Dai, Xuanhao Zhang, Jianying Zhang
  • Patent number: 11523856
    Abstract: A plasma gun for treating a tumor in vivo and a use method thereof. The plasma gun includes a generator component including an ionization device and a shield element, and a discharge component. The ionization device is provided at the shield element, and the discharge component is connected to an end of the shield element. The present invention overcomes the problem that a low-temperature plasma jet cannot contact a tumor in vivo. The plasma gun reaches the interior of the tumor, promoting the treatment of the plasma to the tumors. It is suitable for the application in clinical treatment. As compared with the conventional radiotherapy, chemotherapy and surgery, the present invention has the advantages of selectivity on cancer cells and little side effects. The plasma directly reaches the tumor lesion, which has good therapeutic effect and avoids the impact on normal tissues.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 13, 2022
    Assignee: JIANGSU CAPTAIN BIOTECHNOLOGY CO., LTD.
    Inventors: Xiaofeng Dai, Shaoqing Xiao